Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.

Détails

Ressource 1Télécharger: 29296621_BIB_73E580433B39.pdf (202.20 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_73E580433B39
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Périodique
Annals of clinical and translational neurology
Auteur(s)
Perrotta G., Bonnier G., Meskaldji D.E., Romascano D., Aydarkhanov R., Daducci A., Simioni S., Cavassini M., Metral M., Lazeyras F., Meuli R., Krueger G., Du Pasquier R.A., Granziera C.
ISSN
2328-9503 (Print)
ISSN-L
2328-9503
Statut éditorial
Publié
Date de publication
12/2017
Peer-reviewed
Oui
Volume
4
Numéro
12
Pages
915-920
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.

Pubmed
Web of science
Open Access
Oui
Création de la notice
15/01/2018 18:01
Dernière modification de la notice
20/08/2019 14:31
Données d'usage